Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care
  • Policy / Pricing

Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care

Drug Channels

By Bryce Platt, PharmD Minnesota's new 340B data reveal a growing disconnect between the program's size and the value Minnesotans receive in return.

Policy / PricingRead full story

pharminent April 23, 2026 (Last updated: April 23, 2026)

Drug Channels

By Bryce Platt, PharmD Minnesota’s new 340B data reveal a growing disconnect between the program’s size and the value Minnesotans receive in return.

Policy / PricingRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Sanofi receives FDA approval for Tzield in paediatric diabetes
Next: AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data

Related Stories

  • Policy / Pricing

EFPIA report adds to pressures on EU drug pricing policy

pharminent June 24, 2026
  • Policy / Pricing

US launches probe of German ‘underpayment’ for medicines

pharminent June 19, 2026
  • Policy / Pricing

FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’

pharminent June 19, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.